Research Analysts Set Expectations for SLNO FY2025 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Soleno Therapeutics in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will earn ($2.65) per share for the year, down from their previous estimate of ($1.97). The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41).

A number of other equities analysts also recently commented on SLNO. Robert W. Baird restated an “outperform” rating and issued a $72.00 price objective on shares of Soleno Therapeutics in a report on Monday, December 2nd. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Soleno Therapeutics in a report on Monday. Stifel Nicolaus assumed coverage on shares of Soleno Therapeutics in a research note on Wednesday. They set a “buy” rating and a $74.00 price objective for the company. Finally, Lifesci Capital upgraded shares of Soleno Therapeutics to a “strong-buy” rating in a report on Tuesday, February 4th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $71.20.

Soleno Therapeutics Stock Up 1.2 %

SLNO stock opened at $44.99 on Thursday. The company has a market cap of $1.94 billion, a price-to-earnings ratio of -13.55 and a beta of -1.46. The business has a fifty day simple moving average of $47.20 and a 200-day simple moving average of $49.86. Soleno Therapeutics has a 52 week low of $36.61 and a 52 week high of $60.92.

Insider Activity at Soleno Therapeutics

In related news, CFO James H. Mackaness sold 4,083 shares of Soleno Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $45.41, for a total value of $185,409.03. Following the completion of the transaction, the chief financial officer now directly owns 115,089 shares in the company, valued at approximately $5,226,191.49. This trade represents a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kristen Yen sold 2,340 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $46.18, for a total value of $108,061.20. Following the transaction, the insider now directly owns 76,605 shares in the company, valued at approximately $3,537,618.90. This represents a 2.96 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 17,360 shares of company stock valued at $790,119. Corporate insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Soleno Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SLNO. Janus Henderson Group PLC increased its stake in Soleno Therapeutics by 27.1% during the fourth quarter. Janus Henderson Group PLC now owns 5,188,265 shares of the company’s stock valued at $233,130,000 after purchasing an additional 1,107,166 shares during the last quarter. Nantahala Capital Management LLC grew its position in shares of Soleno Therapeutics by 20.1% during the 4th quarter. Nantahala Capital Management LLC now owns 3,928,966 shares of the company’s stock valued at $176,607,000 after buying an additional 658,518 shares during the last quarter. Avoro Capital Advisors LLC raised its stake in Soleno Therapeutics by 15.8% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,525,000 shares of the company’s stock worth $113,499,000 after acquiring an additional 344,000 shares during the period. Vanguard Group Inc. lifted its holdings in Soleno Therapeutics by 19.2% in the fourth quarter. Vanguard Group Inc. now owns 1,884,533 shares of the company’s stock worth $84,710,000 after acquiring an additional 303,806 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Soleno Therapeutics by 24.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,630,718 shares of the company’s stock valued at $73,301,000 after purchasing an additional 321,223 shares during the last quarter. 97.42% of the stock is owned by institutional investors and hedge funds.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.